Amnion epithelial cells - a novel therapy for ischemic stroke?

Area of Science:

• Neuroscience
• Regenerative Medicine
• Immunology

Background:

• Stroke is a major cause of death and disability, necessitating novel therapeutic strategies.
• Current cell-based therapies face challenges including resource limitations, invasive procedures, immune rejection, and ethical concerns.
• Human amnion epithelial cells (hAECs) are placenta-derived stem cells that circumvent many limitations of other cell types.

Purpose of the Study:

• To evaluate the efficacy of systemically delivered hAECs in preclinical stroke models.
• To determine if hAECs can mitigate ischemic brain injury, inflammation, and functional deficits post-stroke.
• To assess the therapeutic potential of hAECs in non-human primates.

Main Methods:

• Utilized four distinct animal models of ischemic stroke.
• Administered hAECs intravenously at various time points post-stroke onset.
• Assessed histological outcomes, immune cell infiltration, apoptosis, infarct progression, and functional recovery.
• Included studies in young and aged mice of both sexes, as well as non-human primates.

Main Results:

• Systemic hAEC delivery preferentially targeted the spleen and injured brain.
• hAECs limited apoptosis, inflammation, and immune cell infiltration in the brain.
• Treatment attenuated infarct progression and ameliorated functional deficits, even when delayed by 1-3 days.
• Proof-of-principle studies indicated hAEC effectiveness in non-human primates.

Conclusions:

• hAECs demonstrate significant therapeutic potential for stroke by reducing brain injury and improving recovery.
• The unique properties of hAECs, such as their accessibility and low immunogenicity, make them a promising candidate for clinical translation.
• hAECs represent a viable and practical cell-based therapy option for stroke treatment.